drugset / Trial / NCT02828124
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.
Timeline
- Start
- 2016-08-23
- Primary completion
- 2018-01-08
- Completion
- 2018-01-08
Outcome
Outcome not reported
Stopped (Business): “Business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986183 | Unknown | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |